By Gemifys
A growing number of people who have used semaglutide (marketed as Ozempic or Wegovy) for weight management or blood sugar control eventually stop taking it — sometimes due to cost, side effects, insurance changes, or reaching a treatment goal. What’s less widely discussed is that stopping a GLP-1 medication can come with its own adjustment period, and some people report new or returning symptoms in the weeks after their last dose.
This article is general education only. It is not medical advice, and it should not be used to make any decision about starting, stopping, or changing a GLP-1 medication. Any changes to your treatment should be made with, and only with, your prescribing provider.
What research and clinical sources say about stopping GLP-1 medications
Semaglutide and similar GLP-1 receptor agonists work partly by affecting appetite-regulating signals in the brain and gut. According to Cleveland Clinic, when the medication is discontinued, those effects on appetite and satiety tend to fade over subsequent weeks, and some people experience a return of hunger cues and, in some cases, some of the metabolic changes the medication had been helping manage.
The STEP 4 clinical trial, published in JAMA and widely cited in obesity medicine literature, found that participants who switched from semaglutide to placebo experienced weight regain over the following months, underscoring that GLP-1 medications are generally understood as managing an underlying condition rather than “curing” it. Harvard Health similarly frames GLP-1 therapy as an ongoing treatment, in the same way blood pressure or cholesterol medications are typically continued to maintain their effect.
Reports of anxiety, shaking, or restlessness after stopping
Some people describe non-appetite symptoms after discontinuing semaglutide — things like anxiety, jitteriness, or a general sense of restlessness. It’s important to be cautious here: individual anecdotal reports on forums are not the same as established clinical findings, and there could be multiple explanations, including fluctuations in blood sugar as the body readjusts, the psychological experience of anticipating weight or appetite changes, or symptoms that are coincidental rather than caused by the medication change. MedlinePlus, the NIH’s consumer health resource, recommends contacting a healthcare provider about any new or concerning symptoms after stopping a prescription medication rather than assuming a cause without evaluation.
If you experience new symptoms after stopping a GLP-1 medication — physical or psychological — the appropriate next step is to describe them to your prescriber or another qualified clinician, who can consider your full medical history and rule out other causes.
The bottom line
Stopping semaglutide is a legitimate medical decision that many people navigate, but like starting the medication, it’s one best made in partnership with a healthcare provider — not adjusted or timed independently, and not something to self-diagnose based on what others report online. If you’re considering stopping, or have already stopped and are dealing with symptoms that concern you, reach out to your prescriber.
This article does not provide dosing guidance and is not a substitute for professional medical advice. Don’t start, stop, or adjust any medication without talking to your prescriber.
